Clinical trial
Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia…
NCT00458744 · Children's Oncology Group, Other · Withdrawn
Key facts
| NCT number | NCT00458744 |
|---|---|
| Title | Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment |
| Official title | A Phase I Study Of Talotrexin (PT-523) In Children And Adolescents With Recurrent Solid Tumors Or Recurrent/Refractory Leukemias |
| Lead sponsor | Children's Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific |
| Intervention type | Drug, Procedure |
| Interventions | talotrexin, chemotherapy |
| Enrollment | 0 |
| Start date | Feb 1, 2007 |
| Primary completion | Jul 1, 2008 |
| First posted | Apr 11, 2007 |
| Last update posted | Aug 8, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: